Illumina, Inc. (Nasdaq: Ilmn) Bernstein 41 ° Call for Annual Strategic Decision Conference May 28, 2025 2:30 PM ET
Company participants
Jacob Thayen – Executive Director
Conference call participants
Eva Burstein – Bernstein
Eva Burstein
Alright. Thank you all, for Jining. Let’s move on and start. My name is Eve Burstein. There is no relationship with Bernstein or Bernstein research. I cover tools and diagnoses of life sciences. And it is a pleasure to have Jacob Thayen from Illuminina with us today.
Jake, let me make sure we did well. Then, he joined Illumina as CEO in 2023 and previously served as president of the group of life science markets and applied, and the diagnostic and genomic group in Agilent.
Jacob Thayen
Correct.
Eva Burstein
Who informs tonight by the way.
Jacob Thayen
Is that correct?
Eva Burstein
Glot doesn’t have to be there for it. Before that, he was the corporate vice president of R&D in Dako, and spent more than 16 years between the two companies.
Jacob Thayen
That is correct.
Eva Burstein
Alright. I have it. Excellent.
Jacob Thayen
Thanks, Eva.
Eva Burstein
Excellent. Well, thanks. Thanks for being here. I have many questions and I am excited to jump.
But a quick reminder for you. Paloma’s application is open. Send questions. We want to make sure to answer what you have in mind and not only what I have in mind.
So, with that, let’s start.
Question and Answer Session
P – Eve Burstein
So, now you have a leg on your role for a little more than a year. What are the things you have achieved at this time that you were most proud? And how do you think the company is different from the way it was when you inherited it?
About The Author
